Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post hoc remission analysis of OM-85 in uncontrolled moderate to severe asthma
ISRCTN72336993Phase 3Completed
- Sponsor
- Asthma Clinics
- Start
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of OM-85 in asthma and Airways Infection, sponsored by Asthma Clinics. Primary endpoint: Clinical remission of bronchial asthma at 12 months. Started Dec 2025; status: completed.
02
Drugs
OM-85
03
Conditions
asthmaAirways Infection
Beyond the preview
Go deeper on ISRCTN72336993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72336993.